Background Given the increase of nonalcoholic fatty liver disease (NAFLD) in the general population, a similar rise might be expected in autoimmune hepatitis (AIH) patients. Aims We sought to determine the clinical outcome of patients with coincident AIH and NAFLD. Methods We identified all intradepartmental AIH cases, and those meeting study criteria were placed into one of three cohorts: AIH only, AIH and simple steatosis (SS), and AIH and nonalcoholic steatohepatitis (NASH). The following outcome and clinical data were analyzed:
Introduction
Due to the rising levels of diabetes and obesity and the emerging ''epidemic'' of the metabolic syndrome, the burden of nonalcoholic fatty liver disease (NAFLD) in the general population continues to grow [1] [2] [3] [4] . NAFLD has become prevalent to the point where it is now the most common liver disorder in the USA, with current estimates of NAFLD prevalence ranging from 20 to 35 %.
The rising prevalence of NAFLD in the general population carries important diagnostic, therapeutic, and long-term clinical management implications for patients with other kinds of chronic liver disease. As the prevalence of NAFLD in the general population continues to rise, we may expect to see more and more coincidental NAFLD in patients with chronic liver diseases such as chronic viral hepatitis, alcoholic hepatitis, hemochromatosis, alpha-1 antitrypsin deficiency, primary biliary cholangitis, or autoimmune hepatitis (AIH) [5] [6] [7] [8] . This is of clinical concern, as patients who are exposed to two chronic liver diseases may have a worse clinical outcome and worse survival as compared to patients with a single chronic liver disease.
The presence of NAFLD in patients with AIH remains a poorly characterized and rarely described clinical entity. To our knowledge, only 16 cases of AIH-NAFLD co-occurrence have been reported in the literature, and of those, only 8 cases represent AIH co-occurrence with nonalcoholic steatohepatitis (NASH), the more clinicopathologically advanced form of NAFLD [5, [9] [10] [11] [12] [13] . Co-occurrence of AIH and NAFLD is important from a diagnostic standpoint because autoantibodies are known to occur with increased prevalence in patients with NAFLD, as compared to the prevalence of autoantibodies in the general population [9] [10] [11] [12] [13] [14] [15] . This so-called non-organ specific autoimmunity occurs in the absence of traditional autoimmune disease, making the detection and diagnosis of true autoimmune conditions such as AIH challenging. Therapeutically, it is important to accurately recognize NAFLD in AIH because the standard treatment for AIH, glucocorticoids, could potentially worsen NAFLD. Finally, the clinical outcome and prognostic significance of incidental AIH and NAFLD have yet to be characterized.
We performed a retrospective cohort study with the goal of characterizing the diagnostic, histologic, and therapeutic features and long-term clinical outcome of patients with both AIH and NAFLD as compared to AIH patients without NAFLD.
Materials and Methods
The study protocol was approved by the University of Vermont Medical Center Institutional Review Board (IRB#CHRMS12-213). As a retrospective cohort study with minimal risk to the individual, the University of Vermont Medical Center Institutional Review Board approved a waiver for informed consent applicable to all study patients.
Subjects
The clinicopathologic records, index biopsy, and follow-up biopsies of patients with type 1 autoimmune hepatitis accessioned at the Department of Pathology, University of Vermont, in the years 1973-2011 were reviewed. Patient medical charts were surveyed for age, gender, comorbidities (type I or II diabetes mellitus, body mass index (BMI), hyperlipidemia, hypertension), history of alcohol use, presenting symptoms, treatment data, and long-term clinical and histologic outcome data (liver-related and all-cause mortality, liver-related adverse outcomes, and follow-up liver biopsies). Of those patients who received treatment following index biopsy, complete response to treatment was defined as either follow-up biopsy with grade 0 inflammation (histologic response) or normalization of transaminases up to 2 years after having started therapy (biochemical response). The following AIH-specific laboratory data were collected: autoimmune serologies, IgG or globulin levels, and hepatitis B and C serologies. In all patients whose index liver biopsy had been obtained prior to the discovery of the hepatitis C virus, subsequent testing for the virus was performed and documented.
Histologic Review
For identified AIH patients with available clinical data, all index biopsies were histologically reviewed. We used the simplified criteria for the diagnosis of autoimmune hepatitis (SCAIH), as defined by the International Autoimmune Hepatitis Group (IAIHG) in 2008, to classify the histologic features of AIH as ''atypical histology'' (0 points), ''histology compatible with AIH'' (1 point), or ''typical histology'' (2 points) [16] . Grade and stage were assigned according to Batts-Ludwig classification [17, 18] . The presence or absence of steatosis or steatohepatitis was recorded together with an estimation of severity. When steatohepatitis was present, the characteristics were recorded according to the modified Brunt system: acute lobular hepatitis (polymorphonuclear), ballooning degeneration of hepatocytes, and pericellular/perisinusoidal fibrosis [19, 20] .
Inclusion and Exclusion Criteria
The clinical and laboratory data at the time of the index biopsy were combined with the results of the histologic review. Inclusion in the study required a SCAIH score C6. Exclusion criteria were heavy alcohol use ([21 drinks/ week for men and [14 drinks/week for women), positive titers for hepatitis B and/or C, prior liver transplant, and SCAIH score C6 based on clinical criteria without histologic features of AIH.
Retrospective Cohort Outcomes Analysis
All cases of concurrent AIH and NAFLD were identified, and NAFLD cases were further subdivided into simple Dig Dis Sci (2016) 61:2710-2720 2711 steatosis (SS) and NASH. Patients were placed into one of three cohorts (AIH, AIH and SS, and AIH and NASH). The following outcome and clinical data among the three cohorts were analyzed: incidence of all-cause mortality, incidence of liver-related mortality, incidence of liver-related adverse outcome, and prevalence of cirrhosis at the time of index biopsy. Adverse outcome was defined as development of cirrhosis on a biopsy sample, hepatocellular carcinoma (HCC), portal hypertension, ascites, or hepatic encephalopathy. Liver-related mortality was defined as death with a primary cause of complications of cirrhosis and/or hepatocellular carcinoma.
The following histologic outcome data were captured for all three cohorts: time interval to follow-up biopsy (or biopsies) and grade and stage of liver disease. The delta of the grade and the stage were calculated as the grade or stage on first follow-up biopsy minus the grade or stage on index biopsy, respectively.
Statistical Analysis
Statistical analysis was performed on SPSS statistical software package (version 22 for Windows; SPSS Inc, Chicago, IL). Categorical data are presented as number (%). Continuous data are presented as mean (SD). Fisher's exact and Chi-squared tests were performed to compare discrete and categorical data, respectively. Separate twosided p values were calculated for the following comparisons: AIH versus AIH and SS and AIH versus AIH and NASH.
Incidence rate was defined as the number of total events among a cohort, divided by the cumulative follow-up time, multiplied by one hundred. Relative risk and 95 % confidence intervals were calculated from the incidence rates of cohorts that were being compared: AIH versus AIH and SS and AIH versus AIH and NASH. To control for age-related confounding, secondary outcome analysis was performed with exclusion of patients in the second and third decades of life. Follow-up time was defined as the time in years from index biopsy until death or until the end of the study period (2012) in person-years. Several patients were lost to follow-up. In these cases, follow-up time was defined as the time from index biopsy until the time of the last internal medicine or gastroenterology/hepatology clinic note.
Results

Study Population and Prevalence of NALFD
Of the 127 identified AIH index biopsies, 73 met study selection criteria for AIH (Fig. 1 ). Thirty percent (22/73) of 
Clinical Parameters
Overall, the age ranged from 11 to 78, with mean age of 50 (SD 17; Table 1 ). Age distribution demonstrated bimodal pattern, with a large peak in the fifth through seventh decades and a smaller peak clustered in the second decade. Patients presenting at a young age (age \ 30) were all in the AIH cohort. There was an overall female predominance (45 of 73, or 62 %). There was no statistically significant difference in age or gender among the cohorts. The year of index biopsy ranged widely from 1976 to 2011; however, the great majority (93 %) of cases were from the 1990s to the present. The year of index biopsy for patients in the AIH and SS cohort was significantly later than in the AIH cohort (p = 0.039). The presence of NASH was significantly associated with diabetes mellitus type II (p = 0.027), hyperlipidemia (p = 0.008), and hypertension (p = 0.037). The presence of simple steatosis was significantly associated with obesity (p = 0.020) and hypertension (p = 0.008).
Nearly two-thirds of all patients received treatment following index biopsy (48 out of 73, or 66 %; Table 2 ). A small subset of patients initiated treatment prior to the index biopsy (4 out of 73, or 5 %); these patients were relatively well distributed across cohorts (1 AIH patient, 2 AIH and SS patient, and 1 AIH and NASH patient). Two patients (3 % of total) did not receive treatment after the index biopsy but were eventually started on therapy based on the findings of a subsequent follow-up biopsy. In all, 12 patients (16 %) received no treatment at any point during the study period. Reasons for non-treatment included spontaneous remission (N = 1), autoimmune overlap syndrome (N = 3), and cryptogenic cirrhosis (N = 4). Of patients who were treated, slightly less than half received monotherapy with prednisone or less commonly budesonide (24 out of 54, or 44 %). Twenty patients (37 %) were treated with dual or multidrug therapy with a glucocorticoid plus a non-glucocorticoid agent such as 6-mercaptopurine, azathioprine, methotrexate, or mycophenolate mofetil. Ten patients (19 %) were treated exclusively with non-glucocorticoid therapy. There was no statistically significant difference between cohorts when comparing history of treatment or mode of treatment. Of those patients who received treatment following index biopsy, 38 (79 %) had clinical and/or histologic response data available. Overall, 28 of those patients (74 %) demonstrated complete biochemical and/or histologic response. Response rates across cohorts ranged from 71 % response rate in the AIH cohort to 80 % response rates in the AIH and SS and AIH and NASH cohorts. There was no statistically significant difference between cohorts when comparing response rates.
Histologic Features
The overall mean (SD) grade and stage of fibrosis at time of diagnosis was 2.5 (0.73) and 2.7 (0.90), respectively (Table 3) .
Patients with AIH and NASH were more likely to present with histologic features ''compatible with AIH'' (1 point) rather than ''typical for AIH'' (2 points; p = 0.018) and were more likely to present at a lower grade (p = 0.050) as compared to patients in the AIH cohort. There was no significant difference in the mean fibrosis stage for the AIH and NASH cohort; however, when analyzed stage-for-stage, 50 % of NASH patients had cirrhosis at time of index biopsy (stage 4) as compared to 18 % of AIH-only patients (p = 0.032). Biopsy findings in the AIH and SS were equivalent to the AIH cohort with none of the histologic parameters achieving statistical significance. Patients in the AIH and NASH cohort had a higher mean percent steatosis (36 %) when compared to the AIH and SS cohort (24 %; p = 0.0080).
Outcomes Analysis: Clinical Parameters
Patients in the AIH and NASH cohort had significantly increased incidence of adverse events with a statistically significant or near statically significant relative risk of The AIH and NASH cohort was on average 10 years older than the AIH cohort (58 vs. 48 years), although this difference did not achieve statistical significance (Table 1) . Patients in the second and third decade of life were found only in the AIH cohort and were excluded for secondary clinical outcomes analysis (Table 4) . Exclusion of younger patients increased the average age of the AIH cohort to 55 (range 31-75 years, SD 12). Relative risk across all clinical outcome measures decreased following secondary analysis; however, relative risk of liver-related death remained statistically significant (RR 6.49; 95 % CI 1.22-34.6). There was no statistically significant difference in follow-up time among the three cohorts, regardless of whether follow-up time was measured to the first or the last follow-up biopsy. Overall, necroinflammatory grade tended to decrease on follow-up biopsy (mean delta grade -1.2, range -3 to 1.5, SD -1.0). The delta grade was not statistically significant when compared across the three cohorts. The overall delta stage averaged near zero (mean delta stage -0.02, range -2 to 2, SD 0.58). Delta stage was higher in the AIH and SS cohort (mean 1.2, range 0-2, SD 1.0) versus the AIH cohort (mean -0.22, range -2 to 2, SD 1.3; p = 0.03); however, the sample size for the AIH and SS cohort was very small (N = 3). Delta stage was not statistically significant when comparing the AIH and NASH cohort to the AIH cohort. Of note, 50 % of AIH and NASH patients presented with stage 4 at index biopsy (Table 3) , leaving little room for stage progression.
Seventy-six percent of patients with follow-up biopsies (19/25) received treatment following index biopsy (Table 6 ). Across all cohorts, patients who did not receive treatment had a higher delta grade (mean 0.42, SD 0.92) as compared to those patients did receive treatment (mean -1.71, SD 0.90; p \ 0.0005). Delta stage for those who did not receive treatment was higher (mean 0.58, SD 0.92) than for those who did receive treatment (mean -0.21, SD 0.92); however, this parameter did not achieve statistical significance (p = 0.08).
Discussion
This study represents the largest report to date on the diagnostic and therapeutic features and the long-term clinical outcome of patients with coincident AIH and NAFLD. Previously published reports were limited to at most four cases with both AIH and NAFLD, with limited reported therapeutic, histologic and outcome data. Additionally, these previous reports looked exclusively at the prevalence of AIH in a cohort of NAFLD patients, while our study takes the inverse approach, i.e., examining the prevalence of NAFLD in AIH patients.
The major finding of this study is that patients with AIH who were exposed to metabolic damage in the form of NASH were more likely to present with cirrhosis and were more likely to have decreased survival due to liver-related death as compared to AIH patients who did not have NASH. The finding of liver-related death remained significant after modifying the analysis to account for age differences among the cohorts. Similar trends were seen for all-cause mortality and non-fatal liver-related adverse outcome; however, these comparisons did not achieve statistical significance. Although the absolute number of adverse events was low, the AIH and NASH cohort had a disproportionately higher rate of adverse events, suggesting that coincident NASH accelerates the rate of liver damage from AIH. In contrast to the clinical outcome data, the data for histologic changes over time for the AIH and NASH cohort were not different than for the AIH cohort, though our sample size for follow-up biopsies was small.
Patients with uncomplicated steatosis (simple steatosis) did not show any difference in clinical outcome. This suggests that fatty liver disease needs to progress to the more advanced clinicopathologic state of steatohepatitis before physiologic damage becomes significant enough to affect the long-term outcome.
Remarkably, the prevalence of NASH among our cohort of AIH patients (16 %) was higher than the estimated prevalence in the general population, where it has been estimated to be between 3 and 5 % [1, 2] . Furthermore, in our study population the number of NASH cases outnumbered the cases with simple steatosis. The higher prevalence of NASH may be indicative of the increased physiologic burden of having two chronic liver diseases, in that patients with two chronic liver diseases such as AIH and NAFLD may have an increased rate of progression from uncomplicated steatosis to steatohepatitis.
In contrast to NASH prevalence, the overall prevalence of NAFLD in our study population (30 %) closely matches the prevalence data for the general population (estimated at 20-35 %) [1, 2] . Additionally, most of the metabolic syndrome risk factors we analyzed (diabetes mellitus, obesity, hypertension, hyperlipidemia) were significantly associated with both the SS and NASH cohorts. These findings (metabolic syndrome association and a prevalence which is equal to that of the general population) support a coincidental, and not causal, association between NAFLD and AIH. Co-occurrence of AIH and NAFLD presents several diagnostic and therapeutic challenges. Diagnostically, there is both clinical and histologic overlap that can affect the ability to accurately diagnose the presence of both AIH and NAFLD (especially NASH) in the same patient. Clinically, the high prevalence of non-organ specific autoantibodies in NALFD may drive up the IAHG score, resulting in diagnostic confusion. Multiple studies have demonstrated that based on clinical criteria alone, as many as 20 % of NAFLD patients may in fact qualify for a diagnosis of AIH prior to liver biopsy [12] . For this reason, positive histologic findings are mandatory for the diagnosis of AIH as outlined in the IAHG scoring criteria [16] . With regards to histology, AIH and NASH may demonstrate overlapping features. For example, NASH can have portal inflammation. Importantly, the portal inflammation in NASH is primarily lymphocytic with a minimal plasma cell component. Conversely, the histologic features of AIH in the advanced necroinflammatory grades may mimic NASH in that there is extensive lobulitis and parenchymal collapse that notoriously picks up trichrome stain. The histologic overlap may make diagnosis of both disorders on the same biopsy challenging, as evidenced in our current study, where comparison of the study histologic interpretation with the historical surgical pathology report revealed that the diagnosis of NASH was initially missed in 3 of 12 cases in our AIH and NASH cohort (25 %).
Therapeutically, patients who have both AIH and NAFLD present a significant diagnostic dilemma. The standard therapy for AIH is glucocorticoids (usually prednisone, less often budesonide), which could potentially worsen underlying NAFLD. Non-glucocorticoid therapy, such as 6-mercaptopurine, azathioprine, methotrexate, or mycophenolate mofetil, is available and may be less likely to worsen NAFLD. In our study population, the majority of patients (66 %) underwent treatment following the index biopsy, and of all those who were treated, 83 % received glucocorticoid therapy, either singly or in combination with a second non-glucocorticoid agent. There was no statistically significant difference between our NAFLD patients and non-NAFLD patients when looking at history of treatment or treatment modality. Importantly, patients with NAFLD received a similar proportion of glucocorticoid therapy and were not more likely to be treated by alternative non-glucocorticoid measures. An isolated case report demonstrated clinical resolution of both AIH and NASH in a patient treated with prednisone; however, this remains the only case demonstrating proven benefit of prednisone therapy in patients with both AIH and NASH (11) . Therefore, the optimal treatment regimen for patients presenting with both AIH and NAFLD is uncertain at this time. Weight loss and exercise have the strongest evidence for improvement of NASH [21] . While weight loss would seem like a reasonable recommendation for patients with AIH and NASH who are overweight, further study is needed.
This study has several limitations. Lack of available clinical data, especially for those cases originating prior to the year 2000, resulted in the exclusion of several study cases despite the demonstration of convincing histologic features of AIH on microscopic review. While the AIH cohort (N = 51) was of a relatively robust size, the smaller sizes of our AIH and SS cohort (N = 10) and the AIH and NASH cohort (N = 12) limited our ability to perform certain kinds of statistical outcome analysis (Kaplan-Meier survival curves) and multivariate analysis. With a larger cohort of SS and NASH patients, it would be especially informative to report outcome measures after controlling for variables such as history of treatment and/or history of glucocorticoid-specific therapy. Another major limitation was that a substantial number of cases lacked clinical documentation of the cause of death. In those cases, patients were determined to have died of all-cause rather than of liver-related mortality. However, this may have underestimated the overall number of liver-related deaths, especially in the AIH cohort.
In summary, we performed a retrospective cohort study with the goal of characterizing the diagnostic, histologic, and therapeutic features and long-term clinical outcome of patients with coincident AIH and NAFLD as compared to AIH patients without NAFLD. The findings suggest that simultaneous exposure to two chronic liver diseases confers a clinically significant increased level of risk and may warrant closer follow-up and surveillance. Additionally, we found that patients with AIH and uncomplicated steatosis were at no greater risk of adverse outcomes, suggesting that fatty liver disease must progress to a more advanced clinicopathologic state of steatohepatitis before physiologic damage becomes significant enough to alter the long-term outcome.
